Back to company

Eurofins BioPharma Product Testing Denmark Holding A/S: Financial statements 2020

CVR: 37064408

Eurofins BioPharma Product Testing Denmark Holding A/S (CVR 37064408) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -79,990 and a net result of DKK 5,272,479 compared with DKK 3,326,352 the year before. Equity amounted to DKK 15,897,581. The solvency ratio was 25.7%.

Gross Profit
-79,990 kr.
Profit/Loss
5,272,479 kr.
Equity
15,897,581 kr.
Total Assets
61,873,876 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2020--80 t.5.3 mio.15.9 mio.-
2019--81 t.3.3 mio.13.6 mio.-
2018--83 t.8.1 mio.15 mio.-
2017--110 t.910 t.14.4 mio.-
2016--175 t.584 t.14 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Eurofins BioPharma Product Testing Denmark Holding A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2020

Eurofins BioPharma Product Testing Denmark Holding A/S: The 2019 annual report is outJul 1, 2020

Eurofins BioPharma Product Testing Denmark Holding A/S has published its annual report for 2019. Gross profit came to DKK -80,588, and the net result was DKK 3,326,352.

About Eurofins BioPharma Product Testing Denmark Holding A/S

Eurofins BioPharma Product Testing Denmark Holding A/S is a Danish company of the type Aktieselskab based in Galten, founded in 2015. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Stefánia Pcolová. The company is owned by Eurofins Pharma Services LUX Holding SARL. In 2025, the company reported a gross profit of DKK -163,266 and a net result of DKK 8,356,614 compared with DKK -1,877,244 the year before. Equity amounted to DKK 24,787,263.